Acobiom

Back
Company description
French company specialized in the discovery of new Biomarkers and the development of innovative Diagnostics focused on personalized medicine applications: ACOBIOM core business is to develop Patient Stratification & Personalized Medicine via Companion Diagnostics based on new genomics biomarkers
Acobiom is currently involved in late stage clinical trials for companion diagnostics in oncology and neurodegenerative diseases.
Our scientific team is using an unique and patented technological genomic platform based on New Generation Sequencing (NGS) and real-time PCR associated with proprietary bionformatics and biostatistics tools.
The Company has established expertise and proprietary tools based on NGS systems that enable it to meet FDA guidelines in an accurate and effective manner, including FDA submission.
ACOBIOM developed diagnostic based on new blood biomarkers that are able to bring new life to Shelved Assets/Compounds/Molecules, Existing Drug and NME.
1. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Deplanque G et al. Ann Oncol. 2015 Apr 9. pii: mdv133 2. Comparative analysis of resistant and susceptible macrophage gene expression response to Leishmania major parasite. Rabhi I et al. BMC Genomics. 2013 Oct 22;14:723. doi: 10.1186/1471-2164-14-723. 3. MicroRNAs: new candidates for the regulation of the human cumulus-oocyte complex. Assou S et al. Hum Reprod. 2013 Nov;28(11):3038-49. doi: 10.1093/humrep/det321. Epub 2013 Jul 30. 4. The intellectual disability of trisomy 21: differences in gene expression in a case series of patients with lower and higher IQ. Mégarbané A et al. Eur J Hum Genet. 2013 Nov;21(11):1253-9. doi: 10.1038/ejhg.2013.24. Epub 2013 Feb 20. 5. Of mice and men: divergence of gene expression patterns in kidney. Cheval L et al. PLoS One. 2012;7(10):e46876. doi: 10.1371/journal.pone.0046876. Epub 2012 Oct 3. 6. Transcriptomic signature of Leishmania infected mice macrophages: a metabolic point of view Rabhi I et al. PLoS Negl Trop Dis. 2012;6(8):e1763. doi: 10.1371/journal.pntd.0001763. Epub 2012 Aug 21. 7. New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients. Bou Samra E et al. Br J Haematol. 2012 May;157(3):347-56. doi: 10.1111/j.1365-2141.2012.09069.x. Epub 2012 Mar 6.
Areas of activity
Medical diagnostic / companion diagnostic
Skills
Biology
PCR
Pharmacogenetics /pharmacogenomics
Transcriptomics
Pathologies
Cardiovascular diseases
Neurodegenerative diseases
Oncology
Technologies
Genetic testing
Molecular biology, structural and cellular (in vitro)
Address:
1682 rue de la Valsière CS 77394
34184 Montpellier
Country: France
Web site:
Cluster:
Eurobiomed
Contact Contact member